# Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

> **NCT00901147** · PHASE2 · COMPLETED · sponsor: **Singapore General Hospital** · enrollment: 25 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma (Not Otherwise Specified)
- Angioimmunoblastic T-cell Lymphoma
- Extranodal NK/T-cell Lymphoma Nasal Type
- Enteropathy- Type T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant

## Interventions

- **DRUG:** panobinostat and bortezomib

## Key facts

- **NCT ID:** NCT00901147
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00901147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00901147, "Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00901147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*